DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ansuvimab
Ansuvimab
Fnl Operations and Additional Updates
A Short Overview of Ebola Virus Disease
February 2021 EPS Pipeline Report
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
CDER Therapeutic Biologic Products List
Ebola Virus Disease Outbreak in North Kivu, DRC, 2021
761169Orig1s000
Ebanga (Ansuvimab-Zykl) 400Mg/Vial Lyophilized Powder for Injection
Specialty Pipeline MONTHLY UPDATE
Protein Complexes
Ebola in the Age of COVID Slide Deck (Ribner & Mehta)
761172Orig1s000
Therapeutics for EVD: Update from DRC
Risk Assessment and Risk Mitigation Review(S)
Minutes of the 24 October 2020 FNLAC Meeting Was Approved Unanimously
EBANGA™ Safely and Effectively
Neutralizing Antibody Therapeutics for COVID-19
© 2021 Reachmd Page 1 of 2 Diseases
Top View
Ebola and Marburg Virus Diseases Annual Epidemiological Report for 2019
Plan Stratégique Multinational De Préparation Et De Réponse Directives De Planification Opérationnelle
Alphabetical Listing by Name Dod UNIFORM OUTPATIENT
Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Go Or No Go? Vaccine Panel Upstages US Approval Decisions
Ebanga (Ansuvimab)
International Nonproprietary Names for Pharmaceutical Substances (INN)
Multi-Country Strategic Readiness and Response Plan Operational Planning Guidelines
Ebola Virus Disease (EVD)- Updates on Case Management
KEI Comments NIH License to Ridgeback 30March2021
Antibody News You Should Know July 1 - 15, 2020
2020 FDA Drug Approvals Priority Reviews, for Products That Would the FDA Approved 53 Novel Drugs in 2020, the Second Highest Count in Over 20 Years
Monitoring International Trends
Biosimilar Monoclonalantibodies
Cross-Neutralization of SARS-Cov-2 by a Human Monoclonal SARS-Cov Antibody
761172Orig1s000
The Pharmaceutical Industry in 2020. an Analysis of FDA Drug Approvals from the Perspective of Molecules
Protective Pan-Ebolavirus Combination Therapy by Two Multifunctional Human